Plasma concentrations of adrenomedullin and atrial and brain natriuretic peptides in patients with adrenal pheochromocytoma

Hu,Wei; Shi,Lei; Zhou,Pang‑Hu; Zhang,Xiao‑Bin

doi:10.3892/ol.2015.3660

Plasma concentrations of adrenomedullin and atrial and brain natriuretic peptides in patients with adrenal pheochromocytoma

Authors:
- Wei Hu
- Lei Shi
- Pang‑Hu Zhou
- Xiao‑Bin Zhang
View Affiliations

Affiliations: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: September 2, 2015 https://doi.org/10.3892/ol.2015.3660
Pages: 3163-3170

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate any changes in the plasma concentrations of adrenomedullin (ADM), atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in patients with adrenal pheochromocytoma (PC). The plasma concentrations of the three peptides were measured in 45 healthy control individuals and 90 untreated patients with PC, who consisted of 20 normotensive patients, 30 borderline hypertensive patients and 40 hypertensive patients. After 4 weeks of effective antihypertensive therapy for hypertensive PC patients, the concentrations of ADM, ANP and BNP were measured again, and laparoscopic adrenalectomy was then performed for all PC patients with values that were measured 2 weeks later. The plasma concentrations of the three peptides were significantly increased in the borderline hypertensive and hypertensive patients compared with the concentrations in control individuals and normotensive patients. In addition, there were significant differences between the levels of ADM, ANP and BNP in the borderline and hypertensive groups. The plasma ADM concentration was not associated with the blood urea nitrogen levels, serum creatinine levels or glomerular filtration rate, but was correlated with the serum epinephrine, serum norepinephrine and urine vanillylmandelic acid levels. In addition, the ADM concentration was associated with the systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, left ventricular mass index and plasma concentrations of ANP and BNP in the hypertensive patients with PC. After 4 weeks of antihypertensive treatment, the values of the three peptides in the hypertensive patients with PC were not significantly changed. As expected, the values in borderline and hypertensive groups were significantly decreased 2 weeks subsequent to surgery, whereas there were no significant changes in the normotensive group. ADM may participate, along with ANP and BNP, in the mechanisms that counteract further elevation of blood pressure in patients with PC, and there may be an ADM/catecholamine local regulatory mechanism that is important for the control of adrenal medulla functions.

View Figures

View References

1	Shen WT, Grogan R, Vriens M, Clark OH and Duh QY: One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg. 145:893–897. 2010. View Article : Google Scholar : PubMed/NCBI
2	Domi R and Laho H: Management of pheochromocytoma: Old ideas and new drugs. Niger J Clin Pract. 15:253–257. 2012. View Article : Google Scholar : PubMed/NCBI
3	Thouennon E, Pierre A, Yon L and Anouar Y: Expression of trophic peptides and their receptors in chromaffin cells and pheochromocytoma. Cell Mol Neurobiol. 30:1383–1389. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H and Eto T: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. 1993. Biochem Biophys Res Commun. 425:548–555. 2012. View Article : Google Scholar : PubMed/NCBI
5	Wong HK, Cheung TT and Cheung BM: Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis. 1:ii2012.
6	Cheung BM and Tang F: Adrenomedullin: Exciting new horizons. Recent Pat Endocr Metab Immune Drug Discov. 6:4–17. 2012. View Article : Google Scholar : PubMed/NCBI
7	Shimosawa T and Fujita T: Adrenomedullin and its related peptide. Endocr J. 52:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
8	Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K and Nakao K: Adrenomedullin in cardiovascular disease: A useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci. 14:256–267. 2013. View Article : Google Scholar : PubMed/NCBI
9	Arjamaa O and Nikinmaa M: Natriuretic peptides in hormonal regulation of hypoxia responses. Am J Physiol Regul Integr Comp Physiol. 296:R257–R264. 2009. View Article : Google Scholar : PubMed/NCBI
10	Arjamaa O and Nikinmaa M: Hypoxia regulates the natriuretic peptide system. Int J Physiol Pharmacol. 3:191–201. 2011.
11	Arjamaa O and Nikinmaa M: Oxygen and natriuretic peptide secretion from the heart. Int J Cardiol. 167:1089–1090. 2013. View Article : Google Scholar : PubMed/NCBI
12	Arjamaa O: Physiology of natriuretic peptides: The volume overload hypothesis revisited. World J Cardiol. 6:4–7. 2014. View Article : Google Scholar : PubMed/NCBI
13	Clerico A, Giannoni A, Vittorini S and Passino C: Thirty years of the heart as an endocrine organ: Physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 301:H12–H20. 2011. View Article : Google Scholar : PubMed/NCBI
14	Federico C: Natriuretic Peptide system and cardiovascular disease. Heart views. 11:10–15. 2010.PubMed/NCBI
15	Kuhn M: Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol. 166:522–531. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lu WW and Qi YF: Cardiovascular effects and pathophysiological significance of adrenomedullin family peptides. Sheng Li Ke Xue Jin Zhan. 44:177–182. 2013.(In Chinese). PubMed/NCBI
17	Chollet-Dallon E, Stoermann-Chopard C and Martin PY: Could cystatine C replace creatinine as a market of glomerular filtration rate? Revue medicale suisse. 2:582–585. 2006.PubMed/NCBI
18	Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al: 2007 Guidelines for the management of arterial Hypertension: The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 25:1105–1187. 2007. View Article : Google Scholar : PubMed/NCBI
19	Ohta H, Tsuji T, Asai S, Tanizaki S, Sasakura K, Teraoka H, Kitamura K and Kangawa K: A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta. 287:131–143. 1999. View Article : Google Scholar : PubMed/NCBI
20	Grzywa-Celińska A, Celiński R, Kwaśniewska K, Dyczko M, Prystupa A and Mosiewicz J: The usefulness of natriuretic peptides measurements in the diagnostics of chosen cardiovascular diseases. Pol Merkur Lekarski. 34:232–234. 2013.(In Polish). PubMed/NCBI
21	Lenders JW, Eisenhofer G, Mannelli M and Pacak K: Phaeochromocytoma. Lancet. 366:665–675. 2005. View Article : Google Scholar : PubMed/NCBI
22	Miller RA and Ohrt DW: Pheochromocytoma - review and biochemical workup. S D Med. 66:267 269–270. 2013.
23	Marín MR, Arenas MF, Valverde FM, Garaulet ET, Maderuelo MM, Avilés AM, Quirante FP and Blázquez AA: Laparoscopic adrenalectomy for nonfamilial adrenal medullary hyperplasia. JSLS. 17:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
24	Mannelli M, Lenders JW, Pacak K, Parenti G and Eisenhofer G: Subclinical phaeochromocytoma. Best practice & research. Best Pract Res Clin Endocrinol Metab. 26:507–515. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti L, Scagliotti GV, et al: Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 29:298–302. 2006. View Article : Google Scholar : PubMed/NCBI
26	Bełtowski J and Jamroz A: Adrenomedullin-what do we know 10 years since its discovery? Pol J Pharmacol. 56:5–27. 2004.PubMed/NCBI
27	Kato J, Kitamura K and Eto T: Plasma adrenomedullin level and development of hypertension. J Hum Hypertens. 20:566–570. 2006. View Article : Google Scholar : PubMed/NCBI
28	Al-Omari MA, Khaleghi M, Mosley TH Jr, Turner ST, Morgenthaler NG, Struck J, Bergmann A and Kullo IJ: Mid-regional pro-adrenomedullin is associated with pulse pressure, left ventricular mass and albuminuria in African Americans with hypertension. Am J Hypertens. 22:860–866. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bhandari SS, Davies JE, Struck J and Ng LL: The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension. Metabolism. 59:7–13. 2010. View Article : Google Scholar : PubMed/NCBI
30	Coutinho T, Al-Omari M, Mosley TH Jr and Kullo IJ: Biomarkers of left ventricular hypertrophy and remodeling in blacks. Hypertension. 58:920–925. 2011. View Article : Google Scholar : PubMed/NCBI
31	Nishida H, Horio T, Suzuki Y, Iwashima Y, Kamide K, Kangawa K and Kawano Y: Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin. Peptides. 29:599–605. 2008. View Article : Google Scholar : PubMed/NCBI
32	Sergeeva IA and Christoffels VM: Regulation of expression of atrial and brain natriuretic peptide, biomarkers for heart development and disease. Biochim Biophys Acta. 1832:2403–2413. 2013. View Article : Google Scholar : PubMed/NCBI
33	Saito Y: Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol. 56:262–270. 2010. View Article : Google Scholar : PubMed/NCBI
34	Soualmia H, Ayadi I, Omar S, Feki M, Drissa H, Mebazaa A and Kaabachi N: Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension. Clin Lab. 55:120–127. 2009.PubMed/NCBI
35	Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria RD, Alo P, Marinoni EM, Diacinti D and D'Erasmo E: Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res. 33:290–294. 2001. View Article : Google Scholar : PubMed/NCBI
36	Cotesta D, Caliumi C, Alò P, Petramala L, Reale MG, Masciangelo R, Signore A, Cianci R, D'Erasmo E and Letizia C: High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori. 91:53–58. 2005.PubMed/NCBI
37	Vindenes T, Crump N, Casenas R and Wood K: Pheochromocytoma causing cardiomyopathy, ischemic stroke and acute arterial thrombosis: A case report and review of the literature. Conn Med. 77:95–98. 2013.PubMed/NCBI